1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
Delayed Nasdaq  -  04:00 2022-06-24 pm EDT
144.27 USD   +0.71%
06/25Pfizer says tweaked COVID-19 shots boost omicron protection
AQ
06/24INSIDER SELL : Moderna
MT
06/24Moderna COVID-19 shots now an option for older kids in US
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna testing potential monkeypox vaccines

05/24/2022 | 07:44am EDT

May 24 (Reuters) - Moderna Inc is testing potential vaccines against monkeypox in pre-clinical trials as the disease spreads in the United States and Europe.

The World Health Organization said on Tuesday there have been 131 confirmed monkeypox cases and 106 further suspected cases since the first was reported on May 7 outside the countries where it usually spreads.

Moderna did not immediately respond to a request for more details on the monkeypox vaccines.

The U.S. Centers for Disease Control and Prevention said the government was in the process of releasing doses of a smallpox vaccine Jynneos, made by Bavarian Nordic A/S, for use in monkeypox cases.

(Reporting by Leroy Leo in Bengaluru; Editing by Shounak Dasgupta)


© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
BAVARIAN NORDIC A/S 1.09% 242.1 Delayed Quote.-9.93%
MODERNA, INC. 0.71% 144.27 Delayed Quote.-43.20%
All news about MODERNA, INC.
06/25Pfizer says tweaked COVID-19 shots boost omicron protection
AQ
06/24INSIDER SELL : Moderna
MT
06/24Moderna COVID-19 shots now an option for older kids in US
AQ
06/24U.S. CDC backs Moderna's COVID vaccine for teens, older children
RE
06/24The next COVID booster shots will likely be updated for Omicron
RE
06/24Sanofi, GSK variant-specific COVID shot found effective against Omicron
RE
06/24US Public Health Agency Advisers Recommend Moderna's COVID-19 Jab For Ages Six to 17
MT
06/23CDC advisory panel recommends allowing Moderna vaccine for children 6 to 17
AQ
06/23Experts endorse Moderna COVID-19 shots for kids ages 6 to 17
AQ
06/23U.S. CDC advisers back Moderna COVID vaccine for teens, older children
RE
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2022 22 079 M - -
Net income 2022 11 509 M - -
Net cash 2022 18 531 M - -
P/E ratio 2022 5,29x
Yield 2022 -
Capitalization 57 385 M 57 385 M -
EV / Sales 2022 1,76x
EV / Sales 2023 3,54x
Nbr of Employees 2 700
Free-Float 90,6%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Last Close Price 144,27 $
Average target price 213,67 $
Spread / Average Target 48,1%
EPS Revisions
Managers and Directors
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-43.20%57 385
IQVIA HOLDINGS INC.-24.22%40 468
LONZA GROUP AG-32.67%39 851
SEAGEN INC.16.00%33 010
CELLTRION, INC.-13.38%18 371
ICON PUBLIC LIMITED COMPANY-28.76%17 936